Nadofaragene firadenovec and the future of NMIBC care
Dr. Vikram M. Narayan describes treatment advances and next steps in non-muscle invasive bladder cancer.
Vikram M. Narayan, MD, of Emory University, Winship Cancer Institute, Atlanta, GA, discusses next steps with the novel intravesical gene-mediated therapy nadofaragene firadenovec and the overall future of the treatment paradigm for patients with non-muscle invasive bladder cancer (NMIBC).
Narayan says there are promising options, such as nadofaragene firadenovec, emerging for patients with BCG-unresponsive NMIBC. Some of the next steps, according to Narayan, are exploring combination regimens, assessing sequencing strategies, and developing biomarkers to determine which patients might respond best to treatments.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
